of boars against gonadotrop in releasing hormone.
However, once these were eliminated over a period of another 3 months, active immunization
was unable to confer sustained protection at 7 months.
In the European Union, Prevenar 13 is indicated for active immunization
for the prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae in adults aged 50 years and older caused by 13 Streptococcus pneumoniae serotypes.
About Fluzone Intradermal Quadrivalent (Influenza Vaccine) Indication Fluzone Intradermal Quadrivalent vaccine is indicated for active immunization
for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.
In the United States, Prevnar 13 is indicated in adults 50 years of age and older for active immunization
for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F).
Vaccination aims for active immunization
to prevent invasive disease caused by Neisseria meningitidis serogroup C.
The vaccine is for active immunization
for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae.
The approval is for active immunization
against influenza disease caused by the H5N1 A/Vietnam/1203/2004 influenza virus in adults aged 18-64 who may be at an increased risk of exposure to the H5N1 influenza virus.
Food and Drug Administration (FDA) under an accelerated approval pathway for adults 50 years of age and older for active immunization
for the prevention of pneumococcal pneumonia and invasive disease caused by the 13 serotypes contained in the vaccine.
Tenders are invited for Vaccination has to prevent the goal by active immunization
of damage induced by Neisseria meningitidis serogroup C meningitis.
Intellect's has incorporated proprietary safety features into its ANTISENILIN(R) monoclonal antibody and RECALL-VAXTM technology platforms for both passive and active immunization
, respectively to minimize the potential for adverse side-effects by generating antibodies that bind only the toxic beta amyloid and not the Amyloid Precursor Protein.
An injectable influenza vaccine approved for active immunization
of adults ages 18 and older against influenza disease caused by influenza virus subtypes A and B contained in the vaccine.